Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001641172-25-002602
Filing Date
2025-04-03
Accepted
2025-04-03 17:03:50
Documents
13
Period of Report
2024-10-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 72007
  Complete submission text file 0001641172-25-002602.txt   251219

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bixt-20241025.xsd EX-101.SCH 3084
3 XBRL LABEL FILE bixt-20241025_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE bixt-20241025_pre.xml EX-101.PRE 22366
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3677
Mailing Address C/O BIOXYTRAN, INC. 75 2ND AVE, SUITE 605 STE 605 NEEDHAM MA 02494
Business Address C/O BIOXYTRAN, INC. 75 2ND AVE, SUITE 605 STE 605 NEEDHAM MA 02494 617-494-1199
BIOXYTRAN, INC (Filer) CIK: 0001445815 (see all company filings)

EIN.: 262797630 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-35027 | Film No.: 25810571
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)